GlassScriptPhysician profile
Isaiah Pittman
NPI 1588638928
$1,532,062.88
in general payments reported to CMS, 2019-2025
51 companies · $94K in 2025
The $94K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444K · 2020: $292K · 2021: $258K · 2022: $213K · 2023: $151K · 2024: $79K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $237K · Travel and Lodging: $66K · Food and Beverage: $13K · Honoraria: $5,000 · Consulting Fee: $3,600 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $236,799.19 |
| Travel and Lodging | $66,135.45 |
| Food and Beverage | $13,016.25 |
| Honoraria | $5,000.00 |
| Consulting Fee | $3,600.00 |
| Education | $124.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $529,861.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $350,288.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $275,123.84 | 2019-2023 | Farxiga |
| Insulet Corporation | $143,980.25 | 2019-2025 | Omnipod |
| Corcept Therapeutics | $84,167.24 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62,274.75 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $43,281.92 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26,423.46 | 2021-2025 | |
| Eli Lilly and Company | $5,898.97 | 2023 | |
| Amgen INC. | $1,505.12 | 2019-2025 | Repatha, Tepezza, Repatha |
| Cequr Corporation | $882.06 | 2023-2025 | Cequr Simplicity |
| Abbott Laboratories | $794.19 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Dexcom, INC. | $776.50 | 2021-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $710.42 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Amarin Pharma, INC. | $677.25 | 2019-2022 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $652.67 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $627.47 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $606.72 | 2020-2025 | Recorlev |
| Esperion Therapeutics, INC. | $566.35 | 2020-2024 | Nexletol |
| Abbvie INC. | $400.59 | 2019-2025 | |
| Antares Pharma, INC. | $375.15 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Sanofi-Aventis U.S. LLC | $348.10 | 2019-2024 | |
| Amneal Pharmaceuticals LLC | $246.21 | 2019-2025 | Unithroid |
| Alexion Pharmaceuticals, INC. | $183.42 | 2021-2025 | Strensiq |
| Tandem Diabetes Care, INC. | $155.41 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $141.21 | 2022-2025 | Tymlos |
| Recordati_rare_diseases_inc. | $129.36 | 2021-2024 | Isturisa, Signifor Lar |
| Gilead Sciences, INC. | $107.97 | 2023 | |
| Lifescan, INC. | $105.75 | 2020-2022 | |
| Medtronic Minimed, INC. | $93.07 | 2019-2020 | |
| Beta Bionics, INC. | $74.77 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amryt Pharma Holdings LTD | $61.57 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.68 | 2021-2023 | Cycloset |
| Horizon Therapeutics Plc | $54.95 | 2022-2023 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $47.32 | 2019 | |
| Shire North American Group INC | $42.61 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $41.44 | 2021-2022 | |
| Echosens North America, INC. | $36.07 | 2023 | Fibroscan |
| Eusa Pharma (US) LLC | $35.31 | 2022 | |
| Ibsa Pharma INC. | $27.32 | 2022-2023 | Tirosint, Licart |
| Soleno Therapeutics, INC. | $25.82 | 2025 | Vykat Xr |
| Currax Pharmaceuticals LLC | $25.48 | 2020 | |
| Senseonics, Incorporated | $23.00 | 2019 | |
| Ascendis Pharma Endocrinology INC | $19.06 | 2025 | Yorvipath |
| Kowa Pharmaceuticals America, INC. | $17.12 | 2021 | |
| Neurocrine Biosciences, INC. | $17.06 | 2024 | |
| Avvisto Therapeutics, LLC | $15.92 | 2025 | Cycloset |
| Companion Medical, INC. | $15.64 | 2020 | |
| Sequel Med Tech, LLC | $14.24 | 2025 | Twiist |
| Grt US Holding, INC. | $13.90 | 2022 | |
| Zealand Pharma US, INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaiah Pittman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.